SRPT (Sarepta Therapeutics) 5-Year EBITDA Growth Rate : 3.10% (As of Sep. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics 5-Year EBITDA Growth Rate?

Sarepta Therapeutics's EBITDA per Share for the three months ended in Sep. 2024 was $0.49.

During the past 3 years, the average EBITDA Per Share Growth Rate was 6.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 3.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -7.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sarepta Therapeutics was 43.30% per year. The lowest was -116.30% per year. And the median was -1.00% per year.

Competitive Comparison of Sarepta Therapeutics's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Sarepta Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sarepta Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's 5-Year EBITDA Growth Rate falls into.

Sarepta Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Sarepta Therapeutics (NAS:SRPT) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Sarepta Therapeutics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sarepta Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

0L35:UK AB3A:Germany AB3A:Germany S1RP34:Brazil

Address

215 First Street, Suite 415, Cambridge, MA, USA, 02142

Website

https://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

Executives

Ian Michael Estepan	officer: Chief Financial Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Michael Andrew Chambers	director	215 FIRST STREET, CAMBRIDGE MA 02142
Bilal Arif	officer: Chief Tech Ops Officer	215 FIRST STREET, CAMBRIDGE MA 02129
Ryan Edward Brown	officer: SVP, General Counsel	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Kathryn Jean Boor	director	3736 S. MAIN STREET, MARION NY 14505
Wigzell Hans Lennart Rudolf	director	OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Richard Barry	director	285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram	director, officer: President & CEO	2525 DUPONT DR, IRVINE CA 92612
Louise Rodino-klapac	officer: Chief Scientific Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens	director	6701 KAISER DRIVE, FREMONT CA 94555
Joseph Bratica	officer: Principal Financial Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton	officer: SVP, General Counsel	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin	director	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Sandesh Mahatme	officer: Senior Vice President, CFO	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901